5 results
Primary: to assess the longterm safety and tolerability of ambrisentan 5mg in subjects with inoperable CTEPH. Secondary: to collect supportive efficacy data.
The primary objective of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with PAH. This will be assessed by time…
Primary: to assess the efficacy of ambrisentan 5mg after treatment period of 16 weeks, in subjects with inoperable CTEPH. Secondary: safety and tolerability.
To study the incidence of 'sustained' ventricular tachyarrhythmias in patients with HFpEF.
2.2 Primary ObjectiveTo study clinical factors, (blood) biomarkers and genetic markers related to AF progression in patients diagnosed with recent onset self-terminating AF with special reference to hypercoagulability.2.3 Secondary Objectives1. To…